Toll样受体3佐剂联合病毒样颗粒诱导抗HIV体液免疫应答
研究将HIV病毒样颗粒(VLP)与含四种Toll样受体配体的偶联佐剂脂质囊泡(CALV)联用,经鼻内初免加两剂颊部加强免疫C57BL/6小鼠,评估3个月内血清抗体与中和能力。结果显示TLR3配体dsRNA偶联CALV联合VLP诱导最强的抗原结合抗体、交叉亚型抗体、IgG2c类转换及针对HIV MN.3株的中和抗体,并显著增加生发中心B细胞和滤泡辅助T细胞。
要点
- CALV(dsRNA)+VLPs诱导针对Bal gp120和pr55 Gag的最高抗体滴度。
- CALV(dsRNA)+VLPs诱导交叉亚型抗体,96ZM651 gp120抗体滴度高。
- CALV(dsRNA)+VLPs以IgG2c为主,并产生针对MN.3株的最强中和抗体。
核心结论
- CALV(dsRNA)是HIV VLPs的优良佐剂,可诱导Th1样免疫球蛋白谱,延长淋巴结生发中心,增加滤泡辅助T细胞,并产生针对HIV 1A型变异株的中和抗体。
研究设计与样本
- C57BL/6小鼠经鼻内初免后两次颊部加强免疫,比较PBS对照、单独VLPs、CALV+VLPs及VLPs复合CALV与TLR2、TLR3、TLR4或TLR7/8配体的免疫效果,疫苗接种后3个月内检测血清免疫球蛋白和中和能力。
主要发现
- CALV(dsRNA)+VLPs诱导针对重组疫苗抗原B亚型Bal gp120和pr55 Gag的最高滴度抗体。
- CALV(dsRNA)+VLPs诱导交叉亚型抗体,表现为针对C亚型96ZM651 gp120的高滴度抗体。
- CALV(dsRNA)+VLPs主要诱导IgG2c而非IgG1,该应答与Th1样细胞因子相关。
- CALV(dsRNA)+VLP免疫小鼠产生针对HIV MN.3株的最强中和抗体。
- 处死时,与PBS组相比,接受CALV(dsRNA)+VLPs的小鼠生发中心B细胞和滤泡辅助T细胞显著增加。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Human Immunodeficiency Virus (HIV) Virus-Like Particles (VLPs) composed of HIVIIIB Gag and HIVBaL gp120/gp41 envelope are a pseudovirion vaccine capable of presenting antigens in their native conformations. To enhance the immunogenicity of the HIV Env antigen, VLPs were coupled to VesiVax Conjugatable Adjuvant Lipid Vesicles (CALV) containing one of four toll-like-receptor (TLR) ligands, each activating a receptor with distinct cellular localization and downstream pathways. C57BL/6 mice were vaccinated by intranasal prime followed by two sub-cheek boosts and their sera immunoglobulin and neutralizing potency were measured over a duration of 3months after vaccination. PBS control, VLPs alone, CALV+VLPs, and VLPs complexed with CALV and ligands for TLR2 (PAM3CAG), TLR3 (dsRNA), TLR4 (MPLA), or TLR7/8 (resiquimod) were evaluated based on antibody titer, IgG1 and IgG2c class switching, germinal center formation, T follicular cells and potency of neutralizing antibodies. Consistently, the TLR3 ligand dsRNA complexed to CALV and in combination with VLPs (CALV(dsRNA)+VLPs) induced the strongest response. CALV(dsRNA)+VLPs induced the highest titers against the recombinant vaccine antigens clade B Bal gp120 and pr55 Gag. Additionally, CALV(dsRNA)+VLPs induced cross-clade antibodies, represented by high titers of antibody to clade c 96ZM651 gp120. CALV(dsRNA)+VLPs induced predominantly IgG2c over IgG1, a response associated with T helper type 1 (Th1)-like cytokines. In turn, CALV(dsRNA)+VLP immunized mice generated the most potent neutralizing antibodies against HIV strain MN.3. Finally, at time of sacrifice, a significant increase in germinal center B cells and T follicular cells was detected in mice which received CALV(dsRNA)+VLPs compared to PBS. Our results indicate that CALV(dsRNA) is a superior adjuvant for HIV VLPs in generating a Th1-like immunoglobulin profile, while prolonging lymph node germinal centers, T follicular cells and generating neutralizing antibodies to a highly sensitive tier 1A variant of HIV.
引用
- Poteet E, Lewis P, Chen C, et al. Toll-like receptor 3 adjuvant in combination with virus-like particles elicit a humoral response against HIV. Vaccine. 2016. PMID: 27997339. doi:10.1016/j.vaccine.2016.10.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。